Overview

Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy

Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the effects of oral emixustat hydrochloride (emixustat) on aqueous humor biomarkers associated with proliferative diabetic retinopathy (PDR) from baseline to week 12.
Phase:
Phase 2
Details
Lead Sponsor:
Acucela Inc.
Kubota Vision Inc.